Aclaris Therapeutics, Inc. ACRS R2K
Healthcare · Biotechnology · United States
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
READ MORE ›$4.55
+211.64% 1Y
Market & Price
Market Cap
$635.47M
Current Price
$4.55
High / Low (52W)
$5.09 / $1.39
Beta
0.78
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.03
Price to Book
4.42
P/S
75.95
EV/EBITDA
-6.78
Dividend Yield
-
Profitability & Returns
ROCE
-56.20%
ROE
-48.42%
ROA
-24.72%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.15
EPS (TTM)
$-0.56
Balance Sheet & Liquidity
Debt/Equity
1.38
Quick Ratio
4.03
Current Ratio
4.03
Debt
$1.99M
Total Assets
$160.46M
Current Assets
$96.32M
Working Capital
$67.67M
Ownership
Promoter Holding
2.23%
Chg in Prom Hold
0.02%
FII / Inst Holding
79.65%
Chg in FII Hold
-0.00%
Financial Snapshot
Enterprise Value
$532.04M
Total Revenue (TTM)
$8.37M
EBITDA
$-78.47M
Free Cash Flow
$-32.21M
Operating Cash Flow
$-52.20M
Shares Outstanding
139.66M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-35.93%
Profit 5Y
8.43%
Revenue (YoY)
37.20%
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -35.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACRS Aclaris Therapeutics, Inc. R2K | 4.55 | - | $635.47M | - | -56.20% | -48.42% | -35.93% | 8.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 684.00K | 999.00K | 1.12M | 3.68M | 1.12M | 3.67M | 1.26M | 886.00K | 983.00K | 1.41M | 2.05M | 1.45M | 1.78M | 1.82M | 1.66M | 1.45M | 1.53M | 19.02M | 2.53M | 1.87M | 9.28M | 2.40M | 2.77M | - | - | 1.46M | 1.78M | 3.30M | 1.29M | 2.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52M | 1.85M | 2.45M | 1.47M | 1.79M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 231.00K | 245.00K | 151.00K | 2.50M | 435.00K | 160.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -61.00K | -73.00K | 850.00K | -174.00K | 208.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.72M | 16.84M | 17.90M | 22.16M | 22.40M |
| Operating Income | -2.63M | -2.60M | -10.64M | - | -13.14M | -12.99M | -10.81M | - | -12.93M | -15.29M | -18.76M | - | -30.95M | -31.98M | -21.34M | - | -27.05M | -43.60M | -22.86M | -15.51M | -11.38M | -10.46M | -28.53M | -18.01M | -20.30M | -18.91M | -20.99M | -20.87M | -29.92M | -31.82M | -31.58M | -18.93M | -12.85M | - | - | -17.78M | -16.91M | -17.05M | -22.33M | -22.19M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.66M | -16.79M | -16.94M | -22.23M | -22.09M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.62M | -2.59M | -10.63M | -4.71M | -13.04M | -12.87M | -10.69M | -11.47M | -12.56M | -14.84M | -18.19M | -22.93M | -30.23M | -31.22M | -32.74M | -38.55M | -37.56M | -49.88M | -55.32M | -15.59M | -11.60M | -10.66M | -28.75M | -18.16M | -21.15M | -18.79M | -20.53M | -19.95M | -28.16M | -29.57M | -29.26M | -16.94M | -10.99M | - | - | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.57 | -0.34 | -0.35 | -0.31 | -0.31 | -0.30 | -0.42 | -0.42 | -0.41 | -0.24 | -0.15 | - | - | -0.12 | -0.13 | -0.12 | -0.16 | -0.15 |
| R&D Expense | 1.74M | 1.79M | 9.41M | - | 9.54M | 9.84M | 7.16M | - | 7.77M | 7.96M | 10.86M | - | 13.61M | 13.98M | 15.19M | - | 19.64M | 17.52M | 16.18M | 7.68M | 6.47M | 6.24M | 7.84M | 7.90M | 13.98M | 14.31M | 18.78M | 23.66M | 22.59M | 25.27M | 23.88M | 9.85M | 8.76M | 5.96M | - | 11.58M | 11.45M | 13.03M | - | 15.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.68M | 6.15M | 4.23M | 6.48M | - | 29.75M | 31.25M | 18.72M | 7.83M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 11.96M | 18.08M | 15.46M | 7.28M |
| Gross Profit | - | - | - | - | 476.00K | 3.24M | - | - | - | 17.79M | 13.17M | 3.26M | 542.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 102.95M | 129.48M | 55.79M | 74.62M |
| Operating Income | -5.26M | -8.53M | -20.67M | -48.57M | -54.36M | -84.78M | -111.06M | -50.91M | - | -85.15M | -116.31M | -52.53M | -74.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | -84.36M | -115.45M | -51.72M | -73.62M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -86.91M | -88.85M | -132.06M | -64.92M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | 0 | -367.00K | 0 | - |
| Net Income | -5.24M | -8.52M | -20.56M | -48.08M | -68.52M | -132.74M | -161.35M | -51.02M | - | -86.91M | -88.48M | -132.06M | -64.92M |
| Diluted EPS | - | - | - | - | - | - | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | - |
| R&D Expense | 3.49M | 6.51M | 15.34M | 33.48M | 35.80M | 60.84M | 64.17M | 29.34M | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
Compounded Sales Growth
| 5 Years: | -35.93% |
| 1 Year: | 37.20% |
Compounded Profit Growth
| 5 Years: | 8.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +211.64% |
| 6 Months: | +66.67% |
| 3 Months: | +58.54% |
| 1 Month: | +1.79% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 17.38M | 94.08M | 176.09M | 243.51M | 275.57M | 98.30M | 70.78M | - | 254.60M | 197.41M | 220.33M | 160.46M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 231.55M | 128.86M | 125.95M | 96.32M |
| Cash & Equivalents | 19.04M | 9.59M | 10.76M | 9.85M | 30.17M | 20.20M | - | 34.19M | 22.06M | - | 45.28M | 39.88M | 24.57M | 19.96M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 623.00K | 484.00K | 298.00K | 318.00K | - |
| Total Liabilities | - | - | 1.46M | 1.55M | 6.59M | 18.25M | 60.44M | 28.39M | 33.13M | - | 56.98M | 40.23M | 64.77M | 57.38M |
| Current Liabilities | - | - | 1.45M | 1.55M | 6.22M | 12.76M | 27.34M | 22.43M | 14.87M | - | 21.94M | 30.95M | 31.60M | 28.64M |
| Long Term Debt | - | - | - | - | - | - | 29.91M | - | 10.65M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 693.00K | 684.00K | 426.00K | - | - |
| Total Equity | -2.19M | -9.16M | -20.75M | 92.52M | 169.49M | 225.26M | 215.12M | 69.91M | 37.65M | - | 197.62M | 157.18M | 155.55M | 103.08M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 66.69M | 70.89M | 107.85M | 120.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.37M | -34.60M | -54.66M | -100.81M | -96.44M | -38.63M | - | -67.57M | -78.33M | -20.07M | -47.11M |
| Investing Cash Flow | - | -76.95M | -61.90M | -55.69M | 9.37M | 105.68M | 6.39M | - | 12.63M | 46.22M | -69.77M | 48.37M |
| Financing Cash Flow | - | 96.41M | 116.83M | 100.39M | 128.26M | -30.32M | 18.37M | - | 72.87M | 26.71M | 74.54M | -5.86M |
| Capital Expenditure | -417.00K | -507.00K | -232.00K | -1.24M | -1.36M | -1.61M | -453.00K | - | -605.00K | -1.31M | -35.93M | -111.00K |
| Free Cash Flow | - | -20.88M | -34.84M | -55.90M | -102.17M | -98.06M | -39.09M | - | -68.17M | -79.63M | -56.01M | -47.22M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 17.93M | -5.40M | -15.31M | -4.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 28.3% | 52.7% | - | - | - | 59.8% | 42.1% | 17.4% | 6.9% |
| Operating Margin % | - | - | - | - | -3,230.0% | -1,378.3% | -2,627.3% | -785.4% | - | -286.2% | -372.2% | -280.6% | -946.5% |
| Net Margin % | - | - | - | - | -4,071.5% | -2,158.0% | -3,817.2% | -787.0% | - | -292.1% | -283.1% | -705.5% | -829.6% |
| ROE % | 57.1% | 41.0% | -22.2% | -28.4% | -30.4% | -61.7% | -230.8% | -135.5% | - | -44.0% | -56.3% | -84.9% | -63.0% |
| ROCE % | - | -53.6% | -22.3% | -28.6% | -23.6% | -34.2% | -146.4% | -91.1% | - | -36.6% | -69.9% | -27.8% | -56.2% |
Shareholding Pattern
Insiders
2.23%
Institutions
79.65%
Public Float
81.47%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BML Capital Management, LLC | 10.20% | 14.25M | $64.84M |
| 2 | Deep Track Capital, Lp | 6.69% | 9.35M | $42.52M |
| 3 | Blackrock Inc. | 5.30% | 7.41M | $33.70M |
| 4 | RA Capital Management, L.P. | 4.87% | 6.80M | $30.96M |
| 5 | Vivo Capital, LLC | 4.77% | 6.67M | $30.33M |
| 6 | Vanguard Capital Management LLC | 3.70% | 5.17M | $23.51M |
| 7 | Frazier Life Sciences Management, L.P. | 3.53% | 4.93M | $22.41M |
| 8 | Rock Springs Capital Management, LP | 3.20% | 4.47M | $20.35M |
| 9 | Decheng Capital LLC | 2.89% | 4.04M | $18.39M |
| 10 | Adage Capital Partners GP L.L.C. | 2.77% | 3.87M | $17.61M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACRS
No recent headlines available.